SEARCH  web site
COMPANIES
Discover the reality of companies and brands!
TRANSNATIONALE.ORG
Free and independant information on large corporations

Merck & Co., Inc.

Headquarters : P.O. Box 100, One Merck Drive Whitehouse Station, NJ 08889 United States of America United States of America web www.merck.com tel. 908-423-1000 stock : MRK analytics

Brands

name
click to compare prices
» Shop local, ethical and at the best price on Ethishop

« Ethical » rating of Merck & Co., Inc. , group and subsidiaries

Jobs -21% /1998 Pollution 3 Fraud 5 Offshore 15 Sales 24 Bn $.€ /year Profit 65 Bn $.€ /1998 Wage 1353 *min. Influence 16 Infocom 7
[click on the rating for the method or on the number for the data]

year
business
source
2006Merck sells 10% of the vaccines bought in the world.Les Echos
2006Merck is the world's seventh-largest pharmaceutical group.Les Echos
2005Merck is the world's third-largest drugmaker.Bloomberg
» More business descriptions and market shares for Merck & Co., Inc..
subsidiarycountry%source
Genfit France Les Echos
Merck Sharp & Dhome United States of America100
Merck-Medco United States of America100
Schering Plough Corp. United States of America100Les Echos
Sirna Therapeutics Inc United States of America100Reuters
» More subsidiaries of Merck & Co., Inc.
country
address & contact : production type
incentive source
Barbados Barbados
Tradewinds Manufacturing SRL :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Barbados Barbados
Maple Leaf Holdings SRL :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Bermuda Bermuda
Merck Foreign Sales Corporation Ltd :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Bermuda Bermuda
Ruskin Ltd :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Bermuda Bermuda
Merck LMC Cash Management (Bermuda) Ltd. :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Bermuda Bermuda
International Indemnity Ltd. :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Bermuda Bermuda
Merck LMC Cash Management (Bermuda) Ltd :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Bermuda Bermuda
International Indemnity Ltd :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Bermuda Bermuda
Merck Foreign Sales Corporation Ltd. :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Ireland Ireland
Dublin : R&D
Offshore finance, secret bank account, tax haven, shell companies or free zone(s) Les Echos
Mexico Mexico
MEXICO NAUCALPAN 5 7 FRACC. IND. ALCE BLANCO & 5 7269015 :
 Sistema de Informacion de la Industria Maquiladora
Panama Panama
Fregenal Holdings S.A :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Panama Panama
Merck Sharp & Dohme (Panama) S.A. :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)
Philippines Philippines
Merck Sharp & Dohme (Philippines) Inc. :
Offshore finance, secret bank account, tax haven, shell companies or free zone(s)

  • Human impact

year name
photo position; compensation
source
2005Clark, Richard
See the photo of: Clark, Richard Chief Operating Officer;
2005Clark, Richard T.
See the photo of: Clark, Richard T. Chief Executive Officer;
LaPresseAffaires.com
2003Gilmartin, Raymond V
See the photo of: Gilmartin, Raymond V Chief Executive Officer;
LaPresseAffaires.com
2002Anstice, David
See the photo of: Anstice, David Chairman; salary: 1,12 million US$;
2002Gilmartin, Raymond V
See the photo of: Gilmartin, Raymond V Chief Executive Officer; salary: 2,99 million US$;
2002Lewent, Judy
See the photo of: Lewent, Judy Chief Financial Officer; salary: 1,2 million US$; stock-options: 4,74 million US$;
1999Atwater, Brewster H
See the photo of: Atwater, Brewster H Director;
1999Birkin, Derek
See the photo of: Birkin, Derek Director;
1999Birkin, Derek
See the photo of: Birkin, Derek Director;
1999Bossidy, Lawrene A
See the photo of: Bossidy, Lawrene A Director;
1999Bowen, William G
See the photo of: Bowen, William G Director;
1999Davis, Carolyne K
See the photo of: Davis, Carolyne K Director;
1999Elam, Lloyd C
See the photo of: Elam, Lloyd C Director;
1999Exley, Charles C
See the photo of: Exley, Charles C Director;
1999Harrison, William B
See the photo of: Harrison, William B Director;
1999Kelley, William N
See the photo of: Kelley, William N Director;
1999Scolnick, Edward M
See the photo of: Scolnick, Edward M Director;
1999Tatlock, Anne M
See the photo of: Tatlock, Anne M Director;
1999Thier, Samuel O
See the photo of: Thier, Samuel O Director;
1999Weatherstone, Dennis
See the photo of: Weatherstone, Dennis Director;
1998Gilmartin, Raymond V
See the photo of: Gilmartin, Raymond V Chief Executive Officer; salary: 2,61 million US$;
Forbes
year
employees
<>
social impact : country
source
2008
55200
2008
-8400
Internal restructuring: Merck & Co. said it will cut 7,200 jobs in the face of generic competition, regulatory delays and falling sales of its cholesterol pills and cancer vaccine.: United States of America
Bloomberg
2008
-1200
Internal restructuring: Merck is eliminating 1,200 U.S. sales jobs, a week after Food and Drug Administration's surprise rejection of an experimental cholesterol drug called Cordaptive.: United States of America
AP
2005
-7000
Closure/Bankruptcy: Merck will close 5 manufacturing plants, one research site and two preclinical development sites to trim costs by as much as $4 billion through 2010. About half of the job cuts will be in the U.S., Merck said.: United States of America
Bloomberg
2004
-4400
Webfin
2004
-700
AGEFI
2003
62000
2002
78100
2001
69300
1999
62300
1998
57300
year
employees
<>
social impact : country
source
 11 informations, access to subscribers
year
country : consequences
source
2006United States of America brand: Vioxx : Merck must pay $51 million to a retiree who claimed its Vioxx painkiller caused his heart attack and a judge ordered a new trial for a man who lost his case over the drug last year.Bloomberg
2005United States of America brand: Vioxx : A jury decided that Merck provided adequate warning to doctors about health risks associated with its withdrawn painkiller Vioxx and did not commit consumer fraud in marketing the drug. Merck is facing more than 6,500 lawsuits from former Vioxx users who claim to have been harmed by the drug. The drug could have caused between 88000 and 140000 heart attacks in the USA.Reuters
year
country : consequences
source
 2 informations, access to subscribers

  • Subsidy

yearfinancial misdemeanorsalesincome buybacksource
2008   23,97,81   billion US$
2007   3,28   billion US$
2006   4,43   billion US$
2006 Merck pays 2,3 billion dollars of taxes, interests and tax penalties to settle an investigation of the tax authorities of the United States on the recording of its patents since 1993 in countries with low taxation in order to pay less tax.     Les Echos
2005   4,63   billion US$
2005 Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said.     Canadian Press
2004   5,8   billion US$Les Echos
2003   22,496,83   billion US$
2002   51,797,15   billion US$
2001   47,727,28   billion US$
2000   40,366,82 5billion US$SmartMoney
1999   32,715,89   billion US$
1998   26,95,25   billion US$
yearfinancial misdemeanorsalesincomeassetsbuybacksource
 13 informations, access to subscribers
year
purpose : intermediary/lobby : institution
source
2008 : translate
2007As in the United States, Merck's local subsidiary, Merck Frosst Canada, has lobbied aggressively for a government policy mandating blanket vaccination of young girls. Gardasil was approved in Canada in July 2006, and the first doses were given the following month. More recently, its National Advisory Committee on Immunization has recommended blanket vaccination for girls between the ages of nine and thirteen, with older girls and women also receiving "catch up" shots. : translatePR Watch
2001Access to foreign market (through MAI, WTO, GATS), prevent binding environmental regulations : USCIB (US Council For International Business) : : US Government translateUSCIB
2000Limit the legal liability, no price control, no list of preferred drugs, hampers the approval and marketing of generic drugs, no drug imports, no limit to drug advertising… : Pharmaceutical Research and Manufacturers of America : : US government, congress, senate translateWashington Post
2000Investment protection and market access (to Mexico and Canada through NAFTA), to Latin America (through FTAA). : Business Roundtable : : US government, senate, congress translateCenter for Responsive Politics
2000Prevent binding regulation, co- or self-regulation instead. : American Chamber of Commerce's EU Committee : : European Commission translateCorporate Europe Observatory
2000Lift the ban on bovine growth hormons, the moratorium on GMOs : EFPIA (European Federation of Pharmaceutical Industry Associations) : : European Commission translateEFPIA
1999Market access and investment protection (through WTO, GATS), avoid social and environmental rules : ICC (International Chamber of Commerce) : : WTO, GATS translateCorporate Europe Observatory
1998Regulation favorable to company's interests : Contribution to Candidate's Political Action Committee : amount: 262 thousand US$ : US President, Congress, Senate translateCenter for Responsive Politics
1997Legislation favorable to company's interests : Direct donation : amount: 5140 thousand US$ : US President, Congress, Senate translateCenter for Responsive Politics
1997Legislation favorable to company's interests : Direct donation : amount: 235 thousand US$ : US President, Congress, Senate translateCenter for Responsive Politics
» More influence from Merck & Co., Inc.
» Influence in 2007
year
purpose : intermediary/lobby : institution
source
 11 informations, access to subscribers
» More influence from Merck & Co., Inc.
» Influence in 2007
year
dubious practice : image
source
2007Deceptive advertising: Merck will pay 58 million dollars to settle a suit from thirty American States which accused it of haviung made deceptive advertising to praise the merits of its Vioxx anti-inflammatory drug, withdrawn from the market since because of its dangerous side-effects.: Les Echos
2007Disinformation: A comparison of the internal data of Merck in 2001 with the results of two clinical trials made public in 2004 and 2005 reveals "that the presentation of Merck as for the risk of death related to Vioxx among patients suffering from Alzheimer could be minimized intentionally", according to an article of the "Newspaper of the American Medical Association". Merck had voluntarily withdrawn Vioxx of the market September 2004 following a study showing that the drug doubled the risk of cardiovascular accidents after eighteen months of daily use. The internal document was obtained within the frameworks of the lawsuits with which Merck is confronted about Vioxx.: Les Echos
2007Disinformation: In June 2005, U.S. National Public Radio's Snigdha Prakash reported, "New documents obtained by NPR suggest that even as Merck was making Vioxx into a bestseller, the company was putting pressure on independent doctors. The company's apparent aim: to keep them from discussing evidence of Vioxx's potential safety problems. The documents show that Merck exerted pressure not only on individual doctors, but also on several of the nation's top medical schools." NPR described Merck's campaign to recruit the physician Gurkirpal Singh of Stanford University as a Vioxx spokesperson. "Merck wanted Singh on board because he was a senior researcher on a seminal study of arthritis patients," reported Prakash. Starting in 1998, Merck cultivated Singh; the physician soon became a Vioxx booster, being paid $2,500 per speaking engagement by Merck. But in 2000, a study suggesting heart problems among Vioxx users worried Dr. Singh. He asked Merck for the data. "I wanted to know how many heart attacks, how many strokes, how many deaths were occurring in each one of the groups, and what were these actual number of patients at risk, and how many ended up having an event," he told NPR. Merck originally promised to share the information with Singh, but never did. Singh began including his concerns in his public presentations on Vioxx. Merck began closely tracking Dr. Singh's activities. According to NPR: Almost a dozen Merck executives were involved [in tracking Dr. Singh]. A senior regional executive who had supervised Singh's scientific handlers sent this Oct. 4, 2000, e-mail: "I have in excess of 80 e-mails pertaining to interactions with Dr. Singh from March 1999 to present. The following is my best recollection of what has happened. Because of the sensitive nature of the following, I strongly encourage you not to share with anyone unless they clearly have a need to know." As Singh's public criticisms of Vioxx continued ("He was now promoting Vioxx's rival, Celebrex," and "being paid by Pfizer," reported NPR. Merck decided to start calling his superiors at Stanford. Stanford medical professor James Fries told NPR, "I received a call from a medical director at Merck, stating that someone on my staff had been making wild and irresponsible public statements about the cardiovascular side effects of Vioxx." Fries said the Merck representative "hinted there would be repercussions for Fries and Stanford if Singh's statements didn't stop. He was left with the sense that Merck's financial support to Stanford was at risk.": Sourcewatch
2005Disinformation: In June 2005, the ad agency Ogilvy & Mather Worldwide launched the first promotional campaign ever for Merck - a $20 million, 6-month campaign with the slogan "Merck. Where patients come first." The campaign was planned before the company was forced to withdraw its popular painkiller Vioxx, and before evidence came to light that Merck not only ignored evidence that Vioxx caused heart complications, but also heavily marketed the drug. The major goal of the Merck promotional campaign was "to build emotional ties between Merck and consumers": One television commercial shows cute children reacting in charming confusion to requests to define "measles," "mumps" and "chicken pox." "Most kids today don't have a clue about diseases adults remember, thanks to Merck's scientists," a female announcer says, adding: "We've invested billions to research heart disease and asthma. Now we're trying to make Alzheimer's, diabetes and cancer history too." … Also, more than 40 percent of the ads in the campaign are being devoted to information about what Merck calls its access programs, which are efforts to provide some consumers with prescription drugs either free or at reduced prices.: value: Merck. Where patients come first.; Sourcewatch
2005Disinformation: Merck allegedly tried to censor vioxx critics. Merck hired Stanford University's Dr. Gurkirpal Singh in 1998 and paid him up to $2,500 for each talk he gave to other physicians about Vioxx. But when Singh became concerned about a 2000 study suggesting Vioxx increased the risk of heart attacks, Merck tracked Singh's public comments on Vioxx, eventually contacting his bosses at Stanford and hinting "there would be repercussions ... if Singh's statements didn't stop." Merck provides significant research funding to Stanford, a common arrangement between drug companies and universities.: NPR
2005
2005slogan: Merck. Where patients come first.;
2004"APCO Worldwide is supporting Merck's PR efforts for the controversial" -- and deadly -- "arthritis drug Vioxx, which was found to increase heart attack risk in patients," reports O'Dwyer's.: Sourcewatch

Your contributions (0)

Bookmark and Share    en español  en français  in italiano
translate this page in arabic chinese dutch german japanese korean russian
Legal notice © T&C 1999-2010
 CONTRIBUTIONS
Koch industries   consumer - 14 April 2011 at 21h38
Artemis   President, Coulson Realty Group - 18 February 2011 at 00h38
Nestle   Add Product Name: Allen's "Fantales" - 20 December 2010 at 22h46
Cominak compagnie miniere d akouta   Meme - 17 November 2010 at 15h15
Unilever   mr - 6 January 2010 at 10h26
Marathon oil group   Marathon Oil/Angola - 15 December 2009 at 15h31
Marathon oil group   Dude - 15 December 2009 at 15h28
Acsa argentina   Mr. - 26 November 2009 at 19h16